VK2735 vs Tirzepatide vs Retatrutide: 2026 GLP-1 Pipeline Comparison

The approval and commercial success of semaglutide (Wegovy) and tirzepatide (Mounjaro) have transformed the obesity treatment landscape. These GLP-1 receptor agonists achieve weight loss of 15–22% of body weight in clinical trials — results that were considered impossible with pharmacotherapy just a decade ago.

But the pharmaceutical industry is not standing still. The next generation of incretin-based therapies aims to deliver even greater weight loss, improved metabolic outcomes, fewer side effects, and more convenient dosing — including oral formulations that could eliminate the need for injections entirely.

As of early 2026, three compounds represent the cutting edge of this pipeline: tirzepatide (already approved), retatrutide (in Phase 3 trials), and VK2735 (advancing through clinical development). Each takes a slightly different approach to targeting the incretin system, and understanding these differences is crucial for anyone following this rapidly evolving field.

Why this matters for UK patients: The UK has been slower than the US to approve and roll out GLP-1 therapies. Wegovy was approved by the MHRA in 2022 but faced supply constraints through 2024. Mounjaro (tirzepatide) received MHRA approval for type 2 diabetes and obesity. NHS access through NICE pathways has expanded but remains subject to eligibility criteria including BMI thresholds and comorbidities. Understanding the pipeline helps UK patients and clinicians anticipate future options and make informed decisions about current treatments.

The stakes are high. Obesity affects approximately 26% of UK adults, costs the NHS an estimated £6.5 billion annually, and is linked to over 200 comorbidities including type 2 diabetes, cardiovascular disease, and 13 types of cancer. More effective, accessible, and tolerable treatments could have transformative public health impact.

Tirzepatide (marketed as Mounjaro by Eli Lilly) is a dual GIP/GLP-1 receptor agonist — meaning it activates two incretin receptors rather than just one. This dual mechanism appears to produce superior weight loss compared to GLP-1 agonists alone.

Mechanism of action: - Activates GLP-1 receptors: Suppresses appetite, slows gastric emptying, improves insulin secretion - Activates GIP receptors: The GIP component adds complementary metabolic effects. GIP (glucose-dependent insulinotropic polypeptide) plays roles in fat metabolism, insulin secretion, and potentially in adipose tissue biology - The dual activation creates synergistic effects that exceed what either pathway achieves alone

Clinical trial results (SURMOUNT programme): - SURMOUNT-1: 72-week treatment achieved mean weight loss of 22.5% at the highest dose (15mg) versus 2.4% with placebo - SURMOUNT-2 (in type 2 diabetes): 14.7% weight loss with 15mg dose - SURMOUNT-3: Combined with lifestyle intervention, achieved 26.6% weight loss - SURMOUNT-4: Patients who stopped tirzepatide after 36 weeks regained approximately half the lost weight by week 88

Side effect profile: - Gastrointestinal effects remain the primary concern: nausea (up to 33%), diarrhoea (23%), constipation (11%), vomiting (9%) - Most GI effects are transient and manageable with dose titration - Serious concerns include potential pancreatitis risk (rare), gallbladder events, and theoretical thyroid C-cell tumour risk (animal data)

UK availability (2026): - MHRA approved for type 2 diabetes and obesity - NICE recommended for weight management in eligible patients - Available through NHS specialist weight management services and private prescriptions - Weekly subcutaneous injection - Private prescription cost: approximately £150–£250 per month depending on dose

Retatrutide (Eli Lilly, LY3437943) represents the next step in incretin pharmacology: it is a triple agonist targeting GLP-1, GIP, and glucagon receptors simultaneously. This triple mechanism is designed to maximise weight loss while addressing metabolic health from multiple angles.

Mechanism of action: - GLP-1 receptor activation: Appetite suppression, improved insulin secretion, slowed gastric emptying - GIP receptor activation: Complementary metabolic effects, potential fat metabolism benefits - Glucagon receptor activation: Increased energy expenditure, hepatic fat reduction, and thermogenesis. This is the novel addition — glucagon receptor activation increases the body's metabolic rate, meaning you burn more calories at rest

Phase 2 trial results (published in NEJM, 2023): - 48-week treatment achieved mean weight loss of 24.2% at the highest dose (12mg) - At 48 weeks, participants had not yet reached a weight-loss plateau, suggesting further loss was possible with continued treatment - Impressive metabolic improvements: HbA1c reduction, blood pressure improvement, lipid improvements - In a subset analysis, some participants lost over 30% of body weight

Phase 3 programme (TRIUMPH): - Multiple large-scale Phase 3 trials are underway as of 2026 - Trials include general obesity, type 2 diabetes, obstructive sleep apnoea, and MASH (metabolic dysfunction-associated steatohepatitis, formerly NAFLD) - Results expected through 2026–2027

Side effect profile (from Phase 2): - GI side effects similar to other incretins: nausea, diarrhoea, vomiting - Dose-dependent — more pronounced at higher doses - The glucagon component raises theoretical concerns about hepatic glucose output and blood sugar elevation, but trial data showed improved glycaemic control overall - Heart rate increases were observed (mean 3–4 bpm above placebo)

Potential UK timeline: - If Phase 3 results are positive: MHRA filing likely 2027–2028 - NICE appraisal and NHS access: 2028–2029 at earliest - May initially be available through private prescription before NHS rollout

Why retatrutide matters: If the Phase 3 data confirms the Phase 2 results, retatrutide could become the most effective obesity pharmacotherapy ever developed, potentially achieving 25–30% weight loss — approaching the results of bariatric surgery, which remains the current gold standard.

VK2735, developed by Viking Therapeutics, is a dual GIP/GLP-1 receptor agonist with a particularly exciting feature: it is being developed in both injectable and oral formulations. An effective oral GLP-1 therapy could dramatically improve patient compliance and accessibility.

Why oral formulation matters: Current GLP-1 therapies require weekly subcutaneous injections. While modern auto-injectors make this straightforward, many patients are needle-averse, and injection burden contributes to treatment discontinuation. Oral semaglutide (Rybelsus) exists but has lower bioavailability and achieves less weight loss than the injectable form. An oral GLP-1 with efficacy comparable to injectables would be transformative.

Clinical development (as of early 2026):

Injectable VK2735: - Phase 2 VENTURE trial results (2024): Achieved 14.7% weight loss at 13 weeks at the highest dose — a remarkable result for such a short treatment period - Extrapolating the weight loss trajectory suggested potential for 20%+ weight loss with longer treatment - Phase 3 trials initiated

Oral VK2735: - Phase 2 oral formulation trial: Demonstrated clinically meaningful weight loss in early results - The oral bioavailability challenge is being addressed through advanced formulation technology - If successful, would represent a major advance in patient convenience

Mechanism comparison with tirzepatide: - Both target GLP-1 and GIP receptors - VK2735 may have a different receptor binding profile and selectivity ratio, potentially affecting the side effect profile - Viking Therapeutics claims a potentially improved tolerability profile based on early data, but head-to-head trials have not been conducted

The competitive landscape for VK2735: Viking Therapeutics is a smaller biotech company compared to Eli Lilly and Novo Nordisk. This affects development timelines, manufacturing capacity, and commercial reach. However, the GLP-1 market is projected to exceed $100 billion by 2030, providing strong incentives for multiple players.

Potential UK availability: - Phase 3 completion: 2027 estimated - FDA and MHRA filings: 2027–2028 if trials succeed - UK availability: 2028–2029 at earliest - Likely to be available through private prescription first if approved

Here is a structured comparison of the three compounds across key dimensions. Note that direct head-to-head trial data does not exist for most comparisons — these are cross-trial estimates that should be interpreted with caution.

Receptor targets: - Tirzepatide: GLP-1 + GIP (dual) - Retatrutide: GLP-1 + GIP + Glucagon (triple) - VK2735: GLP-1 + GIP (dual)

Maximum weight loss observed: - Tirzepatide: 22.5% (72 weeks, SURMOUNT-1) - Retatrutide: 24.2% (48 weeks, Phase 2 — not yet plateaued) - VK2735: 14.7% (13 weeks, Phase 2 — trajectory suggests 20%+ with longer treatment)

Administration route: - Tirzepatide: Weekly subcutaneous injection - Retatrutide: Weekly subcutaneous injection - VK2735: Weekly subcutaneous injection AND oral formulation in development

Development stage (early 2026): - Tirzepatide: Approved (US, EU, UK) - Retatrutide: Phase 3 - VK2735: Phase 2/3

UK availability: - Tirzepatide: Available now (NHS and private) - Retatrutide: Estimated 2028–2029 - VK2735: Estimated 2028–2029

Estimated private cost (UK, when available): - Tirzepatide: £150–£250/month currently - Retatrutide: Unknown — likely comparable to tirzepatide - VK2735: Unknown — oral formulation may be priced at a premium

Key differentiator: - Tirzepatide: Proven, available now, extensive safety data - Retatrutide: Potentially highest weight loss through triple mechanism - VK2735: Oral formulation potential could transform patient experience

Important caveat: Cross-trial comparisons are notoriously unreliable. Different trials have different patient populations, baseline weights, dietary counselling, and dropout rates. Only randomised head-to-head trials can definitively determine which compound is more effective. Such trials may never be conducted between all three compounds.

For UK patients considering GLP-1 therapy in 2026, the practical implications of the pipeline are significant but require realistic expectations about timelines and access.

Available now (2026): - Semaglutide (Wegovy): NICE-approved for weight management. Available through NHS Specialist Weight Management Services for patients with BMI greater than or equal to 35 (or 30 with comorbidities). Also available via private prescription. - Tirzepatide (Mounjaro): NICE-approved for type 2 diabetes and weight management. Available through NHS and private prescription. - Oral semaglutide (Rybelsus): Available for type 2 diabetes. Lower efficacy than injectable forms.

Coming soon (2027–2029): - Retatrutide and VK2735 may receive approval and become available, initially through private prescription - Oral formulations could make treatment more accessible and acceptable to needle-averse patients - Next-generation compounds from other developers (e.g. amycretin from Novo Nordisk, survodutide from Boehringer Ingelheim) will add further options

Practical advice for UK patients:

1. Do not wait for pipeline drugs. If you meet the criteria for current GLP-1 therapy and would benefit from treatment, the available options (semaglutide, tirzepatide) are already highly effective. Waiting 2–3 years for a marginal improvement in efficacy is rarely in a patient's best interest.

2. NHS access is expanding. NICE has progressively broadened access criteria. Speak with your GP about referral to specialist weight management services. The NHS Long Term Plan includes targets for improving obesity treatment.

3. Be cautious about unregulated peptide alternatives. Some people purchase research-grade semaglutide, tirzepatide, or other GLP-1 agonists from unregulated sources to avoid cost or access barriers. This carries significant risks including uncertain purity, incorrect dosing, and no medical oversight.

4. Lifestyle remains foundational. All GLP-1 trials include dietary and exercise counselling alongside medication. The drugs work best as part of a comprehensive approach to metabolic health, not as standalone solutions.

*This guide is for educational purposes only. GLP-1 medications are prescription-only medicines that should be used under medical supervision. Consult your GP or a specialist for personalised advice.*